26828
The Autism Biomarkers Consortium for Clinical Trials: Clinical Characteristics and Interim Evaluation of Clinical Measures Commonly Used in Clinical Trials
Objectives: To examine the interim characteristics of a large sample, including possible site-specific differences. To examine convergent validity of the clinical battery, particularly for social communication symptoms of ASD. To explore whether standardized lab-based measures of face and emotion recognition discriminate groups and relate to traditional measures of clinical function. To examine interim data for test-retest validity of commonly used clinical measures.
Methods: To date, data are available from the Feasibility phase of the project, which included 25 children with ASD and 26 typically developing controls (4-11 years, FSIQ = 53-133). The presentation will include data from approximately 205 children across two time points at ABC-CT interim analysis.
Results: There were site specific differences in age, but not gender or clinician rating measures: ADOS-2 calibrated severity scores, ADI-R, Vineland-3, or CGI. In terms of convergent validity within the social domain, clinician ratings of social symptom severity (CGI) related to ADOS-2 social affect calibrated severity scores, Vineland-3 socialization, PDDBI Social Pragmatic, and SRS-2 Social Communication (ps < .05), suggesting excellent convergent validity for the CGI with other measures of current social communication symptoms within the group with ASD. The ADI-R social domain, which emphasizes historical symptoms; PDDBI Social Approach; SRS-2 Social Awareness, Social Cognition, Social Motivation; and CASI Autism and Asperger scales were not related to CGI. In contrast, the ADOS-2 social affect calibrated severity score was unrelated to ADI-R social, PDDBI, SRS-2 or CASI scales related to social communication symptoms. Likewise, the ADI-R Social scale was related to only the SRS-2 Social Cognition and Social Motivation and CASI Autism/Asperger’s scales. The Vineland-3 Socialization scale related to all CASI, SRS-2 and PDDBI social and autism scales (ps <.06), and all SRS-2 and PDDBI social scales were related to each other (ps <.05). A standardized lab-based measure of face and emotion recognition (NEPSY-2) discriminated groups (face: t(40)=5.03, p<.001; emotion: t(40)=2.75, p=.009) and face memory related the ADOS-2 social affect scores.
Conclusions: Initial findings from ABC-CT feasibility provide information to guide selection of social measures for clinical trials confirming that traditional measures are feasible in a multisite clinical trial, have varying convergent validity, and are relatively independent from performance-based measures, such as the NEPSY-II. The replication of these findings among a larger sample (N=200), including test-retest reliability over a 6-week period will also be presented.